drugset / Trial / NCT07240376
Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome
Not yet recruiting
90 enrolled
Huazhong University of Science and Technology
Renmin Hospital of Wuhan University · collabWuhan TongJi Hospital · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310. The main questions it aims to answer are: Does drug CM310 relieve the symptoms of participants? What medical problems do participants have when injecting CM310? Researchers will compare CM310 to a placebo (a look-alike substance that contains no drug) to see if CM310 works to treat NARES. Participants will: Inject CM310 or a placebo every 2 weeks for 12 weeks, and follow up for another 8 weeks. Visit the clinic once every 2 weeks for checkups and tests. Keep a diary of their symptoms every day.
Timeline
- Start
- 2025-11-25
- Primary completion
- 2026-12-31
- Completion
- 2027-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CM310 | Monoclonal antibody | 300 mg | Subcutaneous |